Notch in skeletal physiology and disease

• Published in: Osteoporosis international Vol. 29; no. 12; pp. 2611 - 2621
• Main Author: Canalis, E.
• Format: Journal Article
• Language: English
• Published: London Springer London 01-12-2018; Springer Nature B.V
• Subjects: Abnormalities, Multiple - physiopathology; Bone cancer; Bone Diseases - physiopathology; Bone healing; Bone mineral density; Bone Neoplasms - physiopathology; Bone Neoplasms - secondary; Bone remodeling; Bone Remodeling - physiology; Breast cancer; Endocrinology; Homeostasis; Humans; Ligands; Medicine; Medicine & Public Health; Metastases; Notch1 protein; Orthopedics; Osteoblastogenesis; Osteoblasts - physiology; Osteoclastogenesis; Osteoclasts - physiology; Osteoporosis; Osteosarcoma; Prostate; Prostate cancer; Receptor mechanisms; Receptors, Notch - physiology; Review Article; Rheumatology; Sarcoma; Signal transduction; Signal Transduction - physiology; Skeleton; Skeleton - abnormalities; T cell receptors; Osteoblast; Osteoclast; Jagged; Congenital disorders; Notch
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-018-4694-3

Notch (Notch1 through 4) are transmembrane receptors that play a fundamental role in cell differentiation and function. Notch receptors are activated following interactions with their ligands in neighboring cells. There are five classic ligands termed Jagged (Jag)1 and Jag2 and Delta-like (Dll)1, Dll3, and Dll4. Recent work has established Notch as a signaling pathway that plays a critical role in the differentiation and function of cells of the osteoblast and osteoclast lineages and in skeletal development and bone remodeling. The effects of Notch are cell-context dependent, and the four Notch receptors carry out specific functions in the skeleton. Gain- and loss-of-function mutations of components of the Notch signaling pathway result in a variety of congenital disorders with significant craniofacial and skeletal manifestations. The Notch ligand Jag1 is a determinant of bone mineral density, and Notch plays a role in the early phases of fracture healing. Alterations in Notch signaling are associated with osteosarcoma and with the metastatic potential of carcinoma of the breast and of the prostate. Controlling Notch signaling could prove useful in diseases of Notch gain-of-function and in selected skeletal disorders. However, clinical data on agents that modify Notch signaling are not available. In conclusion, Notch signaling is a novel pathway that regulates skeletal homeostasis in health and disease.